– USA, MI – Zomedica Corp. (NYSE American: ZOM), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced the appointment of Sean Whelan to its Board of Directors, replacing Chris Wolfenberg who retired.
“We all are very pleased to be joined by an executive with Sean’s sterling background. His broad and deep experience and expertise in financial matters, as well as his previous service with publicly listed companies, will be an excellent addition to our Board. I look forward to Sean assuming the Chairmanship of our Audit Committee, and to working with him on a wide variety of issues as Zomedica progresses.” said CEO, Robert Cohen
He added: “I also would like to thank Chris Wolfenberg for his service on the Board and his valuable counsel during the time that we worked together.”
About Sean Whelan
Mr. Whelan presently is the CEO of Encore Rehabilitation Services, a provider of outcome-driven therapy services and associated compliance and revenue cycle support services. He also previously served as the Company’s CFO from 2017 to 2018.
From 2019 to 2020, Mr. Whelan served as CFO of Smile America Partners, and from 2018 to 2019 as CFO of Bedrock Manufacturing, LLC. He served from 2010 to 2016 as CFO, secretary, treasurer, and a director of Diplomat, Inc. (NYSE: DPLO), a then publicly-traded specialty pharmacy, where he was responsible for finance, external reporting, and investor relations, strategy, and M&A.
Mr. Whelan served from 2007 to 2010 as CFO of InfuSystem Holdings Inc., a publicly-traded health care services company. Before his various healthcare executive roles, Mr. Whelan held senior finance positions with Ford Motor Company from 1996 through 2007, including serving as accounting director for Automotive Components Holdings, LLC, a then Ford subsidiary.
Mr. Whelan began his career with Deloitte in 1994, serving a diverse set of audit clients in the firm’s Detroit office, and earned his CPA license while with the firm. He holds Bachelor of Business Administration and Master of Accounting degrees, both from the University of Michigan’s Ross School of Business. Mr. Whelan also presently serves (since 2019) on the Board of Directors of OptioRx, a specialty pharmacy company.
Mr. Whelan said: “As a dog and cat owner, I am excited by the prospects of Zomedica’s present and future products. And as a business executive, I am thrilled to partner with Rob and the Board to help nurture that growth.”
Based in Ann Arbor, Michigan, Zomedica is a veterinary health company creating products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica’s mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care.
For more information: https://zomedica.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.